Gain-of-function research can't deliver pandemic predictions. Are there alternatives? - Bulletin of the Atomic Scientists

Comments

Post a Comment

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

Image
Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
Read more

Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association

Image
causes of precapillary pulmonary hypertension :: Article Creator Long-term Oxygen Therapy Improves Exercise Capacity In PH Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42 meters (about 138 feet) over the distances walked at start of the study, "Long-term oxygen therapy in precapillary pulmonary hypertension — SOPHA study," which was published in Scientific Reports. PH is marked by high blood pressure in the pulmonary arteries, the blood vessels that transport blood from the heart to the lungs. Precapillary PH includes PAH, where blood pressure increases due to the narrowing of pulmonary arteries, along with CTEPH, a rare form of p...
Read more